drug-safety
(9)
Techsol Life Sciences makes the handoffs work
A medicine needs more than good science. Techsol Life Sciences connects the databases, decisions and people that carry it through trials, safety monitoring and regulatory review.
Truveta persuaded hospitals to share their memory
Hospitals record millions of lives and struggle to learn from them together. Truveta gave those hospitals a stake in the answer - and is now adding genetics to the medical record.
RxLogix and the Trouble Between the Boxes
Drug safety has a paperwork problem with human consequences. RxLogix is betting that connecting the work matters as much as automating it.
Qinecsa wants drug safety out of the inbox
A medicine’s success can bury its maker in safety reports. Qinecsa has bought and built a business around getting those reports into useful shape - and giving specialists more time to read the warning signs.
3Analytics
3Analytics is building the quiet machinery behind safer drugs and devices - software that reads the literature, watches for warning signals and helps regulated teams act before a data problem becomes a patient problem.
Cipherome, Inc.
Cipherome is a San Jose-based clinical genomics and bioinformatics company on a mission to find the drug that works for each individual. Its no-code platform COMPASS lets researchers transform, query, and analyze massive clinical and genomic datasets - like the 500,000-participant UK Biobank - without writing code, while its Xentinel platform uses explainable AI to predict and reduce adverse drug reactions. Backed by roughly $16-23M through a Series B, the 12-person team pairs Silicon Valley software with Seoul National University biomedical-informatics research.
DopaGE
DopaGE is a Los Angeles-area health education company that trains young adults to prevent, recognize, and respond to drug overdoses through gamified, neuroscience-informed online courses. Built by physicians, neuroscientists, and emergency medical personnel and grown out of the student non-profit T.A.C.O., DopaGE sells annual subscriptions to colleges and offers family training so students can learn life-saving skills - fentanyl awareness, naloxone use, and overdose response - in a format they actually want to complete.
PointCross Life Sciences
PointCross Life Sciences is a Foster City, California software and services company that turns the messy data of drug development into FDA-ready submissions. Through its XBIOM platform and eDataValidator, it standardizes nonclinical and clinical study data to CDISC SEND, SDTM and ADaM formats, runs a Hadoop-based data repository for sponsors, and supplies the U.S. FDA itself with the software reviewers use to read nonclinical submissions. The company quietly powers roughly a quarter of all FDA SEND submissions.
John Balian
John D. Balian, MD is a physician-turned-executive who co-founded ClinChoice, one of the world's larger full-service contract research organizations, and serves as its CEO, International. He spent years inside the FDA, then ran drug safety and regulatory operations at Pfizer, Bristol-Myers Squibb and Johnson & Johnson before building a global CRO spanning the US, Europe and Southeast Asia. He is also a published novelist whose debut, Gray Wolves and White Doves, draws on his Armenian heritage and the Armenian Genocide.